Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL
The XPO1 inhibitor KPT-330 exerts anti-cancer effects through stabilizing p53 and inhibiting the PI3K-AKT pathway, providing a molecular basis for DLBCL treatment. We may provide a potential promising combination therapy for the treatment of DLBCL with p53 mutations.
Authors
- H Liu
- Xiaoyu Huang (ORCID: https://orcid.org/0009-0003-1552-0295)
- Zhimin Bai
- Zenghua Lin
- Xinfeng Wang
- Yong Zhou
Institutions
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
Publication Details
- Journal
- Tumori Journal
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1177/03008916251408273
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00